openPR Logo
Press release

Rheumatoid Arthritis Therapeutics Market to touch an aggregate of to $9.7 billion by 2023 growing at a CAGR of 8.2%

05-10-2018 12:11 PM CET | Health & Medicine

Press release from: HTF Market Intelligence Consulting Private Limited

Rheumatoid Arthritis Therapeutics Market to touch an aggregate

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects joints. It is characterized by synovial inflammation and gradual bone erosion over many years, and disease progression results in stiffness and pain, especially in the hands and feet, which hinders patient mobility. Without treatment, the disease leads to joint destruction and disability.

Request Brochure of the Report: https://www.htfmarketreport.com/sample-report/1068940-rheumatoid-arthritis-therapeutics-in-asia-pacific-market

Sustained Growth in Rheumatoid Arthritis Therapeutics Market over Forecast Period

Advent of biologic disease-modifying anti-rheumatic drugs (DMARD) has boosted the RA market tremendously over the last two decades. Growth is expected to continue at a moderate pace from $5.6 billion in 2016 to $9.7 billion in 2023 at a compound annual growth rate (CAGR) of 8.2% in the Asia-Pacific (APAC) markets of India, Australia, China, South Korea and Japan. Japan accounted for the majority of the market in 2016 with a 65.4% share, followed by China, Australia, India and South Korea with 12.7%, 8.6%, 8.1% and 5.2% respectively.

Recently approved therapies anticipated to have a high impact include Eli Lilly and Incyte’s baricitinib and Sanofi and Regeneron’s sarilumab. Along with recently approved therapies, the entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Johnson & Johnson (J&J) and GlaxoSmithKline (GSK)’s sirukumab, and Galapagos’s filgotinib. Galapagos entered into a global collaboration agreement with Gilead in 2015 to develop and commercialize filgotinib for the treatment of inflammatory indications.

The treatment population is set to grow in the five APAC territories, which is a key driver for growth in market size. The loss of the patent exclusivity of major second-line biologic anti-tumor necrosis factor (TNF) therapies such as Orencia, Humira, and Simponi in the forecast period is not expected to reduce the market size due to slow generic erosion. However, this presents a major barrier to growth in market size, which is anticipated to be modest in spite of the entry of promising pipeline candidates.

Enquire Here For Free Consulting @: https://www.htfmarketreport.com/enquiry-before-buy/1068940-rheumatoid-arthritis-therapeutics-in-asia-pacific-market

Scope of the Report

- The current Asia-Pacific RA market contains novel products, including sirukumab, an anti-IL-6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1 inhibitors; Olokizumab, an anti-IL-6 humanized IgG4 mAb; and RCT-18, a recombinant human B-lymphocyte stimulating factor (BLyS) receptor-antibody fusion protein.

- What are the competitive advantages of the existing novel drugs

- There are over 480 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

- Which classes of novel drugs are most prominent in the pipeline

- What is the potential for pipeline products to address unmet needs in the RA market

- Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.

- How do failure rates vary by stage of development, molecule type, and molecular target

- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development

- Over the 2016-2023 forecast period, the Asia-Pacific RA therapeutics market is expected to increase in value at a compound annual growth rate of 8.2%, from $5.6 billion to over $9.7 billion.

- Which markets make the most significant contribution to the current market size

- What are the epidemiology trends in these markets

- Will new market entrants lead to substantial changes in annual therapy costs

- How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets

- A rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.

- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs

- Licensing deals are the most common form of strategic alliance in the RA therapeutics market, with deal values ranging from under $10m to over $1 billion.

- How do deal frequency and value compare between target families and molecule types

- What were the terms and conditions of key licensing deals

Avail Discount on this 105 pages report @ https://www.htfmarketreport.com/request-discount/1068940-rheumatoid-arthritis-therapeutics-in-asia-pacific-market
Reasons to buy

- Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and biologic registries.

- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.

- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.

- Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.

- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.

- Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia, Japan and South Korea.

- Discover trends in licensing and co-development deals concerning RA products and identify the major strategic consolidations that have shaped the commercial landscape.

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com
Connect with us at
https://www.linkedin.com/company/13388569/
https://plus.google.com/u/0/+Htfmarketreportinsights
https://www.facebook.com/htfmarketintelligence
https://twitter.com/htfmarketreport

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rheumatoid Arthritis Therapeutics Market to touch an aggregate of to $9.7 billion by 2023 growing at a CAGR of 8.2% here

News-ID: 1045821 • Views: 285

More Releases from HTF Market Intelligence Consulting Private Limited

Streaming Analytics Market To Witness Astonishing Growth With Leading Players|Mi …
HTF MI recently introduced new title on “Global Streaming Analytics Market Report 2019” from its database. The report provides study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2025. The Report gives you competition analysis of top manufacturer with sales volume, price, revenue (Million USD) and market share, the top players including IBM, Oracle, Microsoft, SAP, SAS, Software AG, Informatica, Tibco,
Bluetooth LED Bulbs Market - Key Takeaways from Latest publication Released|Digi …
HTF MI recently introduced new title on “Global Bluetooth LED Bulbs Market Report 2019” from its database. The report provides study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2025. The Report gives you competition analysis of top manufacturer with sales volume, price, revenue (Million USD) and market share, the top players including Koninklijke Philips N.V., General Electric Company, Acuity Brands
Cable Gland Plugs : Comparative Market Share Analysis, Know Who’s Gaining Mark …
A new business intelligence report released by HTF MI with title "Global and China Cable Gland Plugs Market Research by Company, Type & Application 2013-2025" is designed covering micro level of analysis by manufacturers and key business segments. The Global and China Cable Gland Plugs Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary
Automotive HVAC System Market - Key Takeaways From Latest Publication Released
A new business intelligence report released by HTF MI with title "Global and China Automotive HVAC System Market Research by Company, Type & Application 2013-2025" is designed covering micro level of analysis by manufacturers and key business segments. The Global and China Automotive HVAC System Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary

All 5 Releases


More Releases for Rheumatoid

Global Rheumatoid Arthritis Drugs Market | MarketResearchReports.biz
Latest industry research report on: Global Rheumatoid Arthritis Drugs Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts The Rheumatoid Arthritis Drugs Market has been comprehensively detailed in the report with special focus on a range of key elements such as market share, forecast and base figures, CAGR, driving factors, growth restraints, and business opportunities. Buyers of the report are expected to be informed about significant
Rheumatoid Arthritis Drugs Sales Market Report 2017
Reports And Markets Publish a New Market Research Report On –"Rheumatoid Arthritis Drugs Sales Market Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-rheumatoid-arthritis-drugs-sales-market-report-2017-1541249 In this report, the global Rheumatoid Arthritis Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis 1.2 Obtainable Treatment for Rheumatoid Arthritis Molecular Mechanism of Antirheumatoids 2.1 Purpose of DMARDs in Rheumatoid Arthritis 2.2 Role of Biological Agents in Rheumatoid Arthritis 2.2.1 TNF- Inhibitors 2.2.2 Interleukin -1 and IL-6 Blockers Classification of Rheumatoid Arthritis Drugs 3.1
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Global Rheumatoid Arthritis Drug Market Outlook 2022
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi and Otezla) have dominated the overall anti-rheumatics market with
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the